 
 |
|
British Woman Celebrates a Year of Living Cancer-Free
Date: July 30, 2009
Client: Coronado Biosciences
Summary: LONDON, UK - It's been a year since fashion designer Joanne Scott went through a cancer treatment that changed her life -- and made history to boot. Ms. Scott, 54, was the first person in the world to receive an injection of tumor-activated natural killer (TaNK) cells as a treatment for leukemia. Her doctors at the Royal Free Hospital in London recommended this experimental therapy after two years of traditional treatments, including chemotherapy and a bone marrow transplant, failed to keep her in remission. Ms. Scott didn't expect it to work. "I thought that I was gonna get really sick again," she said, "like I had before." But the new treatment succeeded where the others had failed, sparking hope among oncologists that TaNK cells could be the key to a new type of advanced cancer therapy.
|
|
|
|
 |
|
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination with INTERFERON-ALPHA and RIBAVIRIN in HCV Patients
Date: July 30, 2009
Client: Anadys
Summary: San Diego, CA – Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced finalization of the protocol for the Company’s Phase II trial of ANA598 in combination with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance of the protocol has been received from the United States Food and Drug Administration (FDA), and patient dosing is expected to commence within the next several weeks.
|
|
|
|
 |
|
Debiopharm and MSM Protein Technologies sign agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
Date: July 30, 2009
Client: Debiopharm
Summary: Lausanne, Switzerland and Medford, MA - Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and MSM Protein Technologies (MSM), a human antibody drug discovery company with world class expertise in targeting multi-spanning membrane proteins, announce the signature of an exclusive agreement for the development and commercialisation of Debio 0929, an antibody targeting a G protein-coupled receptor (GPCR), to be developed into a new oncology therapeutic drug.
|
|
|
|
|
|
|
Swissmedic grants Debiopharm marketing authorisation for Moapar® A new therapeutic avenue for the treatment of sexual deviations
Date: July 21, 2009
Client: Debiopharm
Summary: Lausanne, Switzerland - Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has issued a marketing authorisation for Moapar® 11.25mg, the first 3-month injectable formulation, prescribed for a reversible reduction of serum testosterone to the level of castration in adult men suffering from sexual deviations. Developed by Debiopharm, Moapar® contains a gonadotropin releasing hormone (GnRH) agonist analogue.
|
|
|
|
 |
|
Ardea Biosciences Initiates Phase 2b Clinical Trial of RDEA594, Lead Product Candidate for the Treatment of Gout
Date: July 20, 2009
Client: Ardea Biosciences
Summary: SAN DIEGO, CA – Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced that it has initiated a Phase 2b clinical trial of RDEA594, its lead product candidate in development for the management of hyperuricemia and gout. The Company also announced the selection of RDEA684, a next-generation URAT1 inhibitor, as a development candidate for the same indication.
|
|
|
|
 |
|
Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
Date: July 15, 2009
Client: Cellular Dynamics International
Summary: MADISON, Wis. – Cellular Dynamics International (CDI) today announced that it has exclusively in-licensed a US-issued patent portfolio on optimizing the stem cell differentiation selection process and on using heart cells (cardiomyocytes) in drug testing.
|
|
|
|
 |
|
First Catalog Cancer Biochip for Sequence Capture Now Available from febit
Date: July 13, 2009
Client: Febit
Summary: LEXINGTON, Mass. (USA), and HEIDELBERG, Germany – febit holding gmbh announced today the launch of the first human cancer biochip for HybSelectâ, febit’s highly automated technology for sequence capture, enabling targeted Next-Generation Sequencing (NGS). The new catalog cancer biochip features 115 important genes which are reported to be associated with common types of cancer by the Wellcome Trust Sanger Institute.
|
|
|
|
 |
|
Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatrica’s Room Temperature Storage
Date: July 8, 2009
Client: Biomatrica
Summary: SAN DIEGO, CA – Biomatrica today announced that the Sorenson Molecular Genealogy Foundation (SMGF) will use Biomatrica’s SampleMatrix room temperature storage technology to archive its DNA samples. SMGF will use the SampleMatrix technology in place of ultra-low-temperature freezers for the long-term storage of all newly collected samples. In addition, SGMF will move its collection of previously archived samples from freezers to room temperature storage.
|
|
|
|
|
|
|
Cellular Dynamics International Reprograms Blood Cells into Stem Cells
Date: July 8, 1009
Client: Cellular Dynamics
Summary: MADISON, Wisconsin – Researchers at Cellular Dynamics International (CDI) report the ability to generate pluripotent stem cells, which have the ability to generate all tissue types in the body, from very small volumes of ordinary human blood samples. This significant breakthrough provides a readily obtainable source of pluripotent stem cells from the millions of samples in storage at blood repositories and healthcare institutions worldwide. These findings, announced today, will be presented during a poster session beginning at 4:45 p.m. on July 10 at the ISSCR annual meeting in Barcelona, Spain.
|
|
|
|
 |
|
Amira's Lipid Love Affair - Aaron Bouchie
Date: July 6, 2009
Client: Amira Pharmaceuticals
Summary: Spurred by academic research linking LPA I to idiopathic pulmonary fibrosis, Amira Pharmaceuticals Inc. used its medicinal chemistry expertise in bioactive lipids to design antagonists for preclinical studies. The company presented proof-of-concept data in a mouse model of IPF last week and hopes to enter the clinic next year with the first candidate it could take to market on its own. Lysophosphatidic acid (LPA) is an anionic bioactive lipid that acts through EDG receptors to mediate cell proliferation, platelet aggregation, smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis and tumor cell invasion, LPA also elicits anglogenesis.
|
|
|
|
 |
|
Amira Pharmaceuticals' Experimental Lung Disease Drug May Have Legs
Date: July 1, 2009
Client: Amira Pharmaceuticals
Summary: The story around Amira Pharmaceuticals’ experimental drug AP2966 is beginning to get interesting. Yesterday the San Diego-based respiratory drug company said its experimental drug reduced lung scarring in mice, offering promise that the oral medication might one day be approved to treat pulmonary fibrosis. But it turns out there may be a lot more to this drug.
|
|
|
|
|
